Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CASI Pharma Raises $23 Million in Private Placement

publication date: Oct 13, 2017

CASI Pharma, a US-China biopharma listed in the US, raised $23.3 million in a private placement. The company sold nearly 8 million shares at a price of $3 each, including a warrant to buy 0.2 shares at $3 apiece. CASI's previous close was $3.62. Following the announcement, the stock is trading at $2.77, a 24% drop. CASI, which is headquartered in Maryland with a Beijing R&D operation, in-licensed China rights to a portfolio of three drugs from Spectrum Pharma in exchange for a 20% CASI stake in 2014. The company is currently working to obtain China approval of the drugs. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.